Nonmyeloablative Stem Cell Transplantation As Immunotherapy for Kidney Cancer and Other Metastatic Solid Tumors

Overview

Journal Cytotechnology

Specialties Biotechnology
Genetics

Date 2008 Nov 13

PMID 19002956

Citations 1

Authors

Cristian Carvallo

Richard Childs

Affiliations

Soon will be listed here.

Abstract

Over the past few decades, great strides have been made to advance the field of allogeneic hematopoietic stem cell transplantation. The donor immune mediated graft-vs-tumor effect that follows the procedure is now widely accepted as the most effective form cancer immunotherapy available for patients with a variety of advanced hematological malignancies. Recognition that a transplanted immune system could cure patients with treatment refractory leukemia led to the development of ;low-intensity' conditioning regimens, which have improved the safety of the procedure and broadened the application of allogeneic immunotherapy to a growing list of neoplastic diseases. Here we discuss the investigational use of allogeneic transplantation as immunotherapy for patients with metastatic, treatment-refractory solid tumors.

Citing Articles

Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

Baird K, Fry T, Steinberg S, Bishop M, Fowler D, Delbrook C Biol Blood Marrow Transplant. 2011; 18(5):698-707.

PMID: 21896345 PMC: 3262116. DOI: 10.1016/j.bbmt.2011.08.020.

References

Jiang Y, Cullis J, Kanfer E, Goldman J, Barrett A . T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 1993; 11(2):133-8. View

Pedrazzoli P, Da Prada G, Giorgiani G, Schiavo R, Zambelli A, Giraldi E . Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer. 2002; 94(9):2409-15. DOI: 10.1002/cncr.10491. View

Warren E, Gavin M, Greenberg P, Riddell S . Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol. 1998; 5(6):429-33. DOI: 10.1097/00062752-199811000-00013. View

Rini B, Zimmerman T, Gajewski T, Stadler W, Vogelzang N . Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma. J Urol. 2001; 165(4):1208-9. View

Anderson Jr L, Mori S, Mann S, Savary C, Mullen C . Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res. 2000; 60(20):5797-802. View

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik W, Tosti A . Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562):2097-100. DOI: 10.1126/science.1068440. View

Giralt S, Thall P, Khouri I, Wang X, Braunschweig I, Ippolitti C . Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001; 97(3):631-7. DOI: 10.1182/blood.v97.3.631. View

Lamb Jr L, Henslee-Downey P, Parrish R, Godder K, Thompson J, Lee C . Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996; 5(5):503-9. DOI: 10.1089/scd.1.1996.5.503. View

Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J . Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000; 111(1):18-29. DOI: 10.1046/j.1365-2141.2000.02196.x. View

10.

Barnes D, CORP M, LOUTIT J, NEAL F . Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956; 2(4993):626-7. PMC: 2035298. DOI: 10.1136/bmj.2.4993.626. View

11.

Moscovitch M, Slavin S . Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984; 132(2):997-1000. View

12.

Ohminami H, Yasukawa M, Fujita S . HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 1999; 95(1):286-93. View

13.

Warren E, Greenberg P, Riddell S . Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998; 91(6):2197-207. View

14.

Rosenberg S, Yang J, Topalian S, Schwartzentruber D, Weber J, Parkinson D . Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994; 271(12):907-13. View

15.

Fefer A, Sullivan K, Weiden P, Buckner C, Schoch G, Storb R . Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog Clin Biol Res. 1987; 244:401-8. View

16.

Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S . Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343(11):750-8. DOI: 10.1056/NEJM200009143431101. View

17.

Goldman J, Gale R, Horowitz M, BIGGS J, Champlin R, Gluckman E . Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988; 108(6):806-14. DOI: 10.7326/0003-4819-108-6-806. View

18.

Gambacorti-Passerini C, BERTAZZOLI C, Dermime S, SCARDINO A, Schendel D, Parmiani G . Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers. Clin Cancer Res. 1997; 3(5):675-83. View

19.

Truitt R, Atasoylu A . Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant. 1991; 8(1):51-8. View

20.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, CIVIDALLI G . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998; 91(3):756-63. View